TW470647B - Composition and pharmaceutical combination kit comprising formoterol and budesonide - Google Patents

Composition and pharmaceutical combination kit comprising formoterol and budesonide Download PDF

Info

Publication number: TW470647B
Authority: TW; Taiwan
Prior art keywords: active ingredient; patent application; budesonide; composition; scope
Prior art date: 1996-10-08

Application number

TW086114371A

Other languages

English (en)

Chinese (zh)

Inventor

Jan Trofast

Anders Ullman

Original Assignee

Astra Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-08

Filing date

1997-10-02

Publication date

2002-01-01

1997-10-02 Application filed by Astra Ab filed Critical Astra Ab

2002-01-01 Application granted granted Critical

2002-01-01 Publication of TW470647B publication Critical patent/TW470647B/zh

Links

239000000203 mixture Substances 0.000 title claims abstract description 39
229940021598 formoterol and budesonide Drugs 0.000 title 1
239000004480 active ingredient Substances 0.000 claims abstract description 47
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims abstract description 18
229960004436 budesonide Drugs 0.000 claims abstract description 18
238000011282 treatment Methods 0.000 claims abstract description 11
150000003839 salts Chemical class 0.000 claims abstract description 9
208000023504 respiratory system disease Diseases 0.000 claims abstract description 8
239000012453 solvate Substances 0.000 claims abstract description 8
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 14
GZSCFURMBHMSCE-JKNDIDBPSA-N (6s,8r,9s,10r,13s,14s)-6,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-3,17-dione Chemical group C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@H]21 GZSCFURMBHMSCE-JKNDIDBPSA-N 0.000 claims description 11
NWLPAIVRIWBEIT-SEPHDYHBSA-N (e)-but-2-enedioic acid;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O NWLPAIVRIWBEIT-SEPHDYHBSA-N 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 7
239000003085 diluting agent Substances 0.000 claims description 6
239000000654 additive Substances 0.000 claims description 5
239000000969 carrier Substances 0.000 claims description 4
230000002079 cooperative effect Effects 0.000 claims description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
229940112141 dry powder inhaler Drugs 0.000 claims description 3
239000008101 lactose Substances 0.000 claims description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
229920002307 Dextran Polymers 0.000 claims description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
229930195725 Mannitol Natural products 0.000 claims description 2
230000000996 additive effect Effects 0.000 claims description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
239000008103 glucose Substances 0.000 claims description 2
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
239000000594 mannitol Substances 0.000 claims description 2
235000010355 mannitol Nutrition 0.000 claims description 2
PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 claims 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 1
229910052748 manganese Inorganic materials 0.000 claims 1
239000011572 manganese Substances 0.000 claims 1
239000000126 substance Substances 0.000 claims 1
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 abstract 1
229960002848 formoterol Drugs 0.000 abstract 1
238000000034 method Methods 0.000 description 25
238000010902 jet-milling Methods 0.000 description 12
208000006673 asthma Diseases 0.000 description 11
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 9
229960001021 lactose monohydrate Drugs 0.000 description 9
208000024891 symptom Diseases 0.000 description 7
239000004615 ingredient Substances 0.000 description 4
239000003380 propellant Substances 0.000 description 4
230000006866 deterioration Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003862 glucocorticoid Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
229940037128 systemic glucocorticoids Drugs 0.000 description 3
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
150000004683 dihydrates Chemical class 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
229960001375 lactose Drugs 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
230000004199 lung function Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
239000007921 spray Substances 0.000 description 2
229960000195 terbutaline Drugs 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
MXPVTFCZEQDBIL-UHFFFAOYSA-N (E)-but-2-enedioic acid trihydrate Chemical compound C(C=CC(=O)O)(=O)O.O.O.O MXPVTFCZEQDBIL-UHFFFAOYSA-N 0.000 description 1
RDWVBJSKXIUVEX-TYYBGVCCSA-N (e)-but-2-enedioic acid;formaldehyde Chemical group O=C.OC(=O)\C=C\C(O)=O RDWVBJSKXIUVEX-TYYBGVCCSA-N 0.000 description 1
DHKVCYCWBUNNQH-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(1,4,5,7-tetrahydropyrazolo[3,4-c]pyridin-6-yl)ethanone Chemical group C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)C=NN2 DHKVCYCWBUNNQH-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical class COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
101001025772 Homo sapiens Neutral alpha-glucosidase C Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
102100037413 Neutral alpha-glucosidase C Human genes 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
208000037883 airway inflammation Diseases 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
229940092705 beclomethasone Drugs 0.000 description 1
150000003842 bromide salts Chemical class 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
239000011362 coarse particle Substances 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
229910003460 diamond Inorganic materials 0.000 description 1
239000010432 diamond Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
239000004744 fabric Substances 0.000 description 1
OXZOLXJZTSUDOM-UHFFFAOYSA-N fluoro 2,2,2-trifluoroacetate Chemical compound FOC(=O)C(F)(F)F OXZOLXJZTSUDOM-UHFFFAOYSA-N 0.000 description 1
229960000289 fluticasone propionate Drugs 0.000 description 1
WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
-1 or diacid Chemical compound 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
GEVPUGOOGXGPIO-UHFFFAOYSA-N oxalic acid;dihydrate Chemical compound O.O.OC(=O)C(O)=O GEVPUGOOGXGPIO-UHFFFAOYSA-N 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
229910052716 thallium Inorganic materials 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Medicinal Preparation (AREA)

TW086114371A 1996-10-08 1997-10-02 Composition and pharmaceutical combination kit comprising formoterol and budesonide TW470647B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE9603669A SE9603669D0 (sv)	1996-10-08	1996-10-08	New combination

Publications (1)

Publication Number	Publication Date
TW470647B true TW470647B (en)	2002-01-01

Family

ID=20404167

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW086114371A TW470647B (en)	1996-10-08	1997-10-02	Composition and pharmaceutical combination kit comprising formoterol and budesonide

Country Status (18)

Country	Link
EP (1)	EP0871450A1 (cs)
JP (1)	JP2000502365A (cs)
KR (1)	KR19990071975A (cs)
AR (1)	AR013614A1 (cs)
AU (1)	AU715319B2 (cs)
BR (1)	BR9706822A (cs)
CA (1)	CA2239308A1 (cs)
CZ (1)	CZ176198A3 (cs)
HU (1)	HUP9901674A3 (cs)
MY (1)	MY128337A (cs)
NO (1)	NO982414L (cs)
NZ (1)	NZ330482A (cs)
PL (1)	PL327037A1 (cs)
SE (1)	SE9603669D0 (cs)
SK (1)	SK75198A3 (cs)
TW (1)	TW470647B (cs)
WO (1)	WO1998015280A1 (cs)
ZA (1)	ZA978889B (cs)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9700136D0 (sv) *	1997-01-20	1997-01-20	Astra Ab	New formulation
SE9700134D0 (sv) *	1997-01-20	1997-01-20	Astra Ab	New formulation
US5983956A (en) *	1994-10-03	1999-11-16	Astra Aktiebolag	Formulation for inhalation
US5980949A (en) *	1994-10-03	1999-11-09	Astra Aktiebolag	Formulation for inhalation
SE9700135D0 (sv) *	1997-01-20	1997-01-20	Astra Ab	New formulation
SE9700133D0 (sv) *	1997-01-20	1997-01-20	Astra Ab	New formulation
PL337722A1 (en) *	1997-06-27	2000-08-28	Astra Ab	Novel combination antiasthmatic drugs
SE9703407D0 (sv)	1997-09-19	1997-09-19	Astra Ab	New use
SE9802073D0 (sv)	1998-06-11	1998-06-11	Astra Ab	New use
US6451285B2 (en)	1998-06-19	2002-09-17	Baker Norton Pharmaceuticals, Inc.	Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6290930B1 (en)	1998-12-18	2001-09-18	Baker Norton Pharmaceuticals, Inc.	Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
US6004537A (en) *	1998-12-18	1999-12-21	Baker Norton Pharmaceuticals, Inc.	Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
SE9900834D0 (sv) *	1999-03-09	1999-03-09	Astra Ab	Novel combination
DE19921693A1 (de) *	1999-05-12	2000-11-16	Boehringer Ingelheim Pharma	Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
ES2165768B1 (es)	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
GB0009584D0 (en) *	2000-04-18	2000-06-07	Glaxo Group Ltd	Pharmaceutical compositions
GB0012260D0 (en)	2000-05-19	2000-07-12	Astrazeneca Ab	Novel composition
FI20002216A0 (fi)	2000-10-06	2000-10-06	Orion Yhtymae Oyj	Yhdistelmäpartikkelit astman hoitoon
US6667344B2 (en)	2001-04-17	2003-12-23	Dey, L.P.	Bronchodilating compositions and methods
US20030055026A1 (en) *	2001-04-17	2003-03-20	Dey L.P.	Formoterol/steroid bronchodilating compositions and methods of use thereof
SE0200312D0 (sv)	2002-02-01	2002-02-01	Astrazeneca Ab	Novel composition
SE527069C2 (sv)	2003-06-19	2005-12-13	Mederio Ag	Förfarande och anordning för administrering av läkemedelspulver
TWI359675B (en)	2003-07-10	2012-03-11	Dey L P	Bronchodilating β-agonist compositions
US20050026887A1 (en) *	2003-07-29	2005-02-03	Boehringer Ingelheim International Gmbh	Medicaments for inhalation comprising an anticholinergic and a steroid
AU2007264418B2 (en)	2006-06-30	2012-05-03	Iceutica Pty Ltd	Methods for the preparation of biologically active compounds in nanoparticulate form
EP2124915A2 (en)	2007-02-19	2009-12-02	Cipla Limited	Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
EP2100599A1 (en)	2008-03-13	2009-09-16	Laboratorios Almirall, S.A.	Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
PL3111927T3 (pl)	2009-05-29	2020-06-29	Pearl Therapeutics, Inc.	Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy
EP2510928A1 (en)	2011-04-15	2012-10-17	Almirall, S.A.	Aclidinium for use in improving the quality of sleep in respiratory patients
US8633178B2 (en)	2011-11-23	2014-01-21	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
NZ629438A (en) *	2012-02-28	2016-10-28	Iceutica Holdings Inc	Inhalable pharmaceutical compositions
ITMI20130571A1 (it)	2013-04-10	2014-10-11	Zambon Spa	Composizione farmaceutica contenente budesonide e formoterolo
IT202000006442A1 (it)	2020-03-27	2021-09-27	Genetic S P A	Budesonide 21-phosphate salts and pharmaceutical compositions containing the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0613371T3 (da) *	1991-12-18	2002-05-13	Astrazeneca Ab	Ny kombination af formoterol og budesonid

1996
- 1996-10-08 SE SE9603669A patent/SE9603669D0/xx unknown
1997
- 1997-09-24 CA CA002239308A patent/CA2239308A1/en not_active Abandoned
- 1997-09-24 AU AU45782/97A patent/AU715319B2/en not_active Ceased
- 1997-09-24 BR BR9706822A patent/BR9706822A/pt not_active IP Right Cessation
- 1997-09-24 HU HU9901674A patent/HUP9901674A3/hu unknown
- 1997-09-24 EP EP97944242A patent/EP0871450A1/en not_active Withdrawn
- 1997-09-24 PL PL97327037A patent/PL327037A1/xx unknown
- 1997-09-24 WO PCT/SE1997/001606 patent/WO1998015280A1/en not_active Ceased
- 1997-09-24 SK SK751-98A patent/SK75198A3/sk unknown
- 1997-09-24 JP JP10517442A patent/JP2000502365A/ja active Pending
- 1997-09-24 KR KR1019980704266A patent/KR19990071975A/ko not_active Withdrawn
- 1997-09-24 CZ CZ981761A patent/CZ176198A3/cs unknown
- 1997-09-24 NZ NZ330482A patent/NZ330482A/xx unknown
- 1997-10-02 TW TW086114371A patent/TW470647B/zh not_active IP Right Cessation
- 1997-10-03 ZA ZA9708889A patent/ZA978889B/xx unknown
- 1997-10-07 AR ARP970104615A patent/AR013614A1/es not_active Application Discontinuation
- 1997-10-07 MY MYPI97004698A patent/MY128337A/en unknown
1998
- 1998-05-27 NO NO982414A patent/NO982414L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CZ176198A3 (cs)	1998-09-16
ZA978889B (en)	1998-04-08
HUP9901674A2 (hu)	1999-09-28
AU715319B2 (en)	2000-01-20
HUP9901674A3 (en)	2001-04-28
SE9603669D0 (sv)	1996-10-08
KR19990071975A (ko)	1999-09-27
MY128337A (en)	2007-01-31
PL327037A1 (en)	1998-11-09
NZ330482A (en)	1999-11-29
WO1998015280A1 (en)	1998-04-16
AR013614A1 (es)	2001-01-10
NO982414D0 (no)	1998-05-27
SK75198A3 (en)	1998-11-04
JP2000502365A (ja)	2000-02-29
EP0871450A1 (en)	1998-10-21
CA2239308A1 (en)	1998-04-16
AU4578297A (en)	1998-05-05
BR9706822A (pt)	1999-03-23
NO982414L (no)	1998-05-27

Legal Events

Date	Code	Title	Description
2002-04-18	GD4A	Issue of patent certificate for granted invention patent
2009-10-11	MM4A	Annulment or lapse of patent due to non-payment of fees

Publication	Publication Date	Title
TW470647B (en)	2002-01-01	Composition and pharmaceutical combination kit comprising formoterol and budesonide
JP3342484B2 (ja)	2002-11-11	新規な配合
CN100389771C (zh)	2008-05-28	含有福莫特罗和布地奈德的组合物在制备预防和治疗急性气喘疾病的药物的应用
AU777827B2 (en)	2004-11-04	Aerosol formulations and devices for increasing libido in women via acute testosterone administration
KR100234864B1 (ko)	1999-12-15	기도 및 폐질환을 치료하기 위한 모메타손푸로에이트 약제
CA2302700C (en)	2010-11-23	New use for budesonide and formoterol
JP2005539046A (ja)	2005-12-22	特異的な抗コリン作用薬、β−２アゴニスト、および副腎皮質ステロイドを含む、治療薬および組成物
JPH03167120A (ja)	1991-07-19	呼吸疾患治療薬
JPH03167119A (ja)	1991-07-19	呼吸疾患治療薬
US20100136121A1 (en)	2010-06-03	Medicaments
JP2002510310A (ja)	2002-04-02	抗喘息薬の新規配合
MXPA06008240A (es)	2006-08-31	Metodos de tratamiento.
TWI495466B (zh)	2015-08-11	用於氣喘之吸入性複方組合物
JP2002527351A (ja)	2002-08-27	気道感染に関連した風邪及びインフルエンザ様症状の予防及び治療用組成物
EP1749531B1 (en)	2015-07-22	Use of an oral suspension comprising megestrol acetate for the treatment of bronchial asthma
Mukherjee	1999	Flixotide Nebules: new for chronic severe asthma
MXPA98004357A (en)	1999-02-24	New combination
HK1169334A1 (en)	2013-01-25	Inhaled combination product for asthma
EP1175204A1 (en)	2002-01-30	Aerosol formulations and devices for increasing libido in women via acute testosterone administration
MXPA99011676A (en)	2000-05-01	New combination of antiasthma medicaments
HK1169334B (en)	2014-12-05	Inhaled combination product for asthma
CN1204964A (zh)	1999-01-13	新的组合物